News
亞洲生技大展
Spirit Scientific Biotech: Innovating regenerative medicine by turning biomaterials into pharmaceuticals
Spirit Scientific Biotech is participating in the BIO Asia-Taiwan exhibition for the first time. The well-known media outlet conducted a interview video with us. Steven D. Lin, co-founder and chairman of Spirit Scientific Biotech, made his first appearance at BIO Asia-Taiwan, sharing the company's innovative plans in the field of regenerative medicine. Spirit Scientific Biotech focuses on the pharmaceutical and standardization of biomaterials. Their core technology, BMLT, can significantly improve the stability and shelf life of biomaterials. Their first product, Platelet Lyphoilized Treatment (PLT), is currently the safest
Spirit Scientific biotech debuts at BIO Asia with key lyophilization technology, enabling precise PRP medicine
Spirit Scientific biotech, leader in regenerative medicine, made its debut at BIO Asia-Taiwan 2025. The company showcased its core BMLT®, which transforms biomaterials into stable, quantifiable, and lyophilized forms. This technology's key application is in enhancing traditional PRP (platelet-rich plasma) therapy. By preparing a precise, consistent Platelet Lyophilized Treatment(PLT) product, Spirit Scientific biotech eliminates the variability of standard PRP injections. With over 36,000 cases and partnerships with more than 1,300 medical institutions, the company is now seeking new collaborations to expand its technology's applications. Spirit Scientific biotech has also established
